Featured Research

from universities, journals, and other organizations

Presence Of Gene Mutation Tightly Linked To Drug Effectiveness In Lung Cancer

Date:
April 30, 2004
Source:
NIH/National Cancer Institute
Summary:
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa) will show a beneficial response, researchers announced.

Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) — part of the National Institutes of Health — and two other institutions announced today in the online version of Science*. Previously, gefitinib had been shown to cause tumor regression in certain patients, but researchers had not been able to predict which patients would be responsive to the drug. With this discovery, doctors will be able to select those lung cancer patients who could most benefit from gefitinib and may identify additional patients with other types of cancer who may respond to similar treatments.

The mutation discovered was in the epidermal growth factor receptor (EGFR), a gene that codes for an enzyme in the tyrosine kinase family of proteins. Tyrosine kinases are a class of enzymes involved in cellular signaling that have been shown to undergo mutations in various cancers. Inhibition of this type of enzyme has recently been a focus for scientists, but gefitinib had not been as effective as some had expected based on earlier clinical trials conducted in Japan.

The gene mutations identified in this study cause the kinase to be overactive. The sensitivity to gefitinib in both patients entered into a clinical trial and to tumor cells grown in a lab was shown to be highly correlated with the presence of tumors that contained these EGFR mutations. While this type of drug sensitivity was shown earlier for the drug imatinib (Gleevec™), which is most effective against certain leukemias and gastrointestinal stromal tumors that possess specific genetic mutations, this is the first demonstration of a targeted therapy in a common adult malignancy.

"One of the more striking results we found in this study was the difference in response between Japanese and American patients, which raises the question of genetic variation in different ethnic, cultural, and geographic groups to this particular drug," said Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, who led the Lung Cancer Biology Section at NCI before leaving for Dana-Farber.

To conduct the study, researchers examined 58 lung cancer tumors from Japan (Nagoya City University Hospital) and 61 tumors from the United States (Harvard Medical School). They also examined additional tumors from U.S. patients who had demonstrated a response to gefitinib. The presence of EGFR mutations and the best clinical response to gefitinib therapy occurred most frequently in women, non-smokers, and in patients with a certain type of lung cancer called adenocarcinoma.

Gene mutations were seen in 26 percent of Japanese NSCLC cancer patients vs. only 2 percent of American patients. Japanese women with adenocarcinoma showed the highest percentage of EGFR mutations (57 percent) and also showed the best clinical response to gefitinib. Lung cancer is the leading cause of cancer death in the United States and worldwide for both men and women.

"This is another example of successfully exploiting our ever-increasing understanding of the genetic aberrations of cancer," said Andrew C. von Eschenbach, M.D., director, NCI. Understanding how to maximize the benefits of anti-EGFR treatments should improve the outcome for many patients with lung cancer. In addition, the larger percentage of EGFR mutations in patients from Japan compared to the United States is striking and raises many unanswered questions, suggesting new avenues for basic research, as well as new considerations in the design of clinical trials.

For information about cancer, please visit the NCI home page at http://cancer.gov or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

* Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson, BE, Meyerson M. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, Online publication, April 29, 2004.


Story Source:

The above story is based on materials provided by NIH/National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Cancer Institute. "Presence Of Gene Mutation Tightly Linked To Drug Effectiveness In Lung Cancer." ScienceDaily. ScienceDaily, 30 April 2004. <www.sciencedaily.com/releases/2004/04/040430053520.htm>.
NIH/National Cancer Institute. (2004, April 30). Presence Of Gene Mutation Tightly Linked To Drug Effectiveness In Lung Cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2004/04/040430053520.htm
NIH/National Cancer Institute. "Presence Of Gene Mutation Tightly Linked To Drug Effectiveness In Lung Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/04/040430053520.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins